Zacks Investment Research lowered shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

A number of other equities research analysts also recently weighed in on CVRS. BidaskClub downgraded Corindus Vascular Robotics from a hold rating to a sell rating in a research note on Friday, September 8th. ValuEngine raised Corindus Vascular Robotics from a sell rating to a hold rating in a research note on Thursday, June 22nd. Finally, Cowen and Company set a $3.00 price target on Corindus Vascular Robotics and gave the stock a buy rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $2.67.

Shares of Corindus Vascular Robotics (NYSEMKT:CVRS) traded down 2.53% during mid-day trading on Wednesday, hitting $1.54. The stock had a trading volume of 58,906 shares. The firm’s market cap is $288.44 million. The company has a 50-day moving average of $1.69 and a 200 day moving average of $1.44. Corindus Vascular Robotics has a one year low of $0.40 and a one year high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Corindus Vascular Robotics had a negative return on equity of 94.27% and a negative net margin of 372.63%. On average, equities research analysts forecast that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Corindus Vascular Robotics Inc (CVRS) Downgraded to “Hold” at Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/14/corindus-vascular-robotics-inc-cvrs-downgraded-to-hold-at-zacks-investment-research.html.

Several hedge funds have recently modified their holdings of CVRS. Bank of New York Mellon Corp raised its stake in shares of Corindus Vascular Robotics by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock valued at $214,000 after acquiring an additional 9,684 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Corindus Vascular Robotics by 73.3% in the 1st quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock valued at $882,000 after acquiring an additional 284,855 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Corindus Vascular Robotics by 240.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock valued at $375,000 after acquiring an additional 201,900 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Corindus Vascular Robotics by 67.6% in the 2nd quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after acquiring an additional 32,608 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Corindus Vascular Robotics by 184.7% in the 2nd quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock valued at $312,000 after acquiring an additional 108,745 shares in the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Stock Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related stocks with our FREE daily email newsletter.